Abstract:In this study we exploit a large panel of gastric cancer (GC) cell lines and powerful (phospho)proteomic workflows to provide the most comprehensive characterization of the GC proteome to date. The data are used to generate novel subclassifications and we identify, and then validate through functional analyses and interrogation of publicly available data, kinase targets for broad or precision GC treatment. Different molecular classifications for gastric cancer (GC) have been proposed based on multi‐omics platforms with the long‐term goal of improved precision treatment. However, the GC (phospho)proteome remains incompletely characterized, particularly at the level of tyrosine phosphorylation. In addition, previous multiomics‐based stratification of patient cohorts has lacked identification of corresponding cell line models and comprehensive validation of broad or subgroup‐selective therapeutic targets. To address these knowledge gaps, we applied a reverse approach, undertaking the most comprehensive (phospho)proteomic analysis of GC cell lines to date and cross‐validating this using publicly available data. Mass spectrometry (MS)‐based (phospho)proteomic and tyrosine phosphorylation datasets were subjected to individual or integrated clustering to identify subgroups that were subsequently characterized in terms of enriched molecular processes and pathways. Significant congruence was detected between cell line proteomic and specific patient‐derived transcriptomic subclassifications. Many protein kinases exhibiting 'outlier' expression or phosphorylation in the cell line dataset exhibited genomic aberrations in patient samples and association with poor prognosis, with casein kinase I isoform delta/epsilon (CSNK1D/E) being experimentally validated as potential therapeutic targets. Src family kinases were predicted to be commonly hyperactivated in GC cell lines, consistent with broad sensitivity to the next‐generation Src inhibitor eCF506. In addition, phosphoproteomic and integrative clustering segregated the cell lines into two subtypes, with epithelial–mesenchyme transition (EMT) and proliferation‐associated processes enriched in one, designated the EMT subtype, and metabolic pathways, cell–cell junctions, and the immune response dominating the features of the other, designated the metabolism subtype. Application of kinase activity prediction algorithms and interrogation of gene dependency and drug sensitivity databases predicted that the mechanistic target of rapamycin kinase (mTOR) and dual specificity mitogen‐activated protein kinase kinase 2 (MAP2K2) represented potential therapeutic targets for the EMT and metabolism subtypes, respectively, and this was confirmed using selective inhibitors. Overall, our study provides novel, in‐depth insights into GC proteomics, kinomics, and molecular taxonomy and reveals potential therapeutic targets that could provide the basis for precision treatments.

Crizotinib‐based PROTAC suppresses gastric cancer via promoting MET degradation

Crizotinib‐based Proteolysis Targeting Chimera Suppresses Gastric Cancer by Promoting MET Degradation

P-053 MET Overexpression and Amplification Define a Distinct Molecular Subgroup for Targeted Therapies in Gastric Cancer

Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.

Establishment of Patient-Derived Gastric Cancer Xenografts: a Useful Tool for Preclinical Evaluation of Targeted Therapies Involving Alterations in HER-2, MET and FGFR2 Signaling Pathways

PROTACs in gastrointestinal cancers

Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification

Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations

Identifying novel therapeutic targets in gastric cancer using genome-wide CRISPR-Cas9 screening

The Significance of MET Expression and Strategies of Targeting MET Treatment in Advanced Gastric Cancer

Multiple Receptor Tyrosine Kinase Activation Attenuates Therapeutic Efficacy of the Fibroblast Growth Factor Receptor 2 Inhibitor AZD4547 in FGFR2 Amplified Gastric Cancer.

Overcoming Chemoresistance in Cancer: The Promise of Crizotinib

Selective and Orally Bioavailable c-Met PROTACs for the Treatment of c-Met-Addicted Cancer

Overcoming Cancer Drug Resistance Utilizing PROTAC Technology

The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells

Proteome‐based molecular subtyping and therapeutic target prediction in gastric cancer

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy

Versatile Nano‐PROTAC‐Induced Epigenetic Reader Degradation for Efficient Lung Cancer Therapy